SEC Form 4 · accession 0001209191-18-025141
Insys Therapeutics, Inc. · INSY
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Saeed Motahari
Officer — President & CEO · Director
Period of report
Apr 17, 2018
Accepted (ET)
Apr 17, 2018 · 2:27 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001516479
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Apr 17, 2018 | A | 11,000 | $0.00 | A | 26,400 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF1,F2 | — | Apr 17, 2018 | D | 11,000 | D | — | — | Common Stock | 11,000 | 22,000 | D |
Explanation of responses
- F1Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
- F2On April 17, 2017, the Reporting Person received a 33,000 share restricted stock unit award ("RSUs"). The RSUs vest in 3 equal annual installments beginning on April 17, 2018 and will be fully vested on April 17, 2020, in all cases so long as there has been no break in the Reporting Person's continuous service through such date.